GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

GSK is enlisting the aid of China’s Chongqing Zhifei Biological Products (Zhifei ... also call upon it to help it distribute new shot Arexvy. Herpes zoster vaccine Shingrix for shingles has ...

The company is banking on Arexvy to become its next blockbuster product amid patent expiries and declining revenue from its current bestsellers in the coming years. Despite Pfizer Inc's (NYSE ...